Add-on Acquisition • Life Science

Rhythm Pharmaceuticals Acquires Xinvento

On February 27, 2023, Rhythm Pharmaceuticals acquired life science company Xinvento

Acquisition Context

This is Rhythm Pharmaceuticals’ 2nd transaction in the Life Science sector.
This is Rhythm Pharmaceuticals’ 1st transaction in the Netherlands.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	February 27, 2023
Target	Xinvento
Sector	Life Science
Buyer(s)	Rhythm Pharmaceuticals
Deal Type	Add-on Acquisition

Target Company

Xinvento

Amsterdam, Netherlands

Xinvento is a biotech company focused on developing therapies for congenital hyperinsulinism (CHI). Xinvento was founded in 2021 and is based in Amsterdam, Netherlands.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Rhythm Pharmaceuticals

Boston, Massachusetts, United States

Category	Company
Founded	2008
Sector	Medical Products

DESCRIPTION

Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in gastrointestinal diseases and obesity, including obesity caused by genetic deficiencies in the MC4 pathway.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	1 of 1
Country: Netherlands	1 of 1
Year: 2023	1 of 1

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2016-10-27	Motus Therapeutics Boston, United States Motus Therapeutics, Inc. is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2016-10-27

Motus Therapeutics

Boston, United States

Motus Therapeutics, Inc. is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases.

Buy

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Netherlands M&A - 2023 M&A